...27 Dec 2010 11:10
Cyprotex, the preclinical ADME Tox services company, said today it has made solid progress following the integration of Apredica and Cellumen.
Company expect full year results for the period to end-December to be in line with market expectations as described in the most recently published analyst note.
Dr Anthony D Baxter, CEO, said: "Following our acquisition of Apredica in August and the introduction of our new CellCiphr(TM) toxicology suite, we are pleased to report good, steady progress in trading. We expect our numbers to be in line with market expectations and our ongoing investment programme reflects our continued confidence in the future prospects for Cyprotex." [StockMarketWire.com]